www.daylifenews.in
Dr. Anar Modi has been featured in the prestigious Avendus Wealth Hurun India Uth Series 2025 U40 List, a recognition that celebrates India’s most promising entrepreneurs under the age of 40 who are shaping the nation’s future through vision, resilience and scale.
The Avendus Wealth Hurun India Uth Series is a merit-based platform that honours young leaders building impactful businesses at an early stage, while demonstrating long-term thinking, governance and responsible leadership. Dr. Modi’s inclusion in the U40 list highlights her entrepreneurial excellence and contribution to India’s evolving business ecosystem.
As Chief Heart Officer at Senores, she leads people-centric initiatives focused on empathy, mental wellbeing, and holistic employee development. Along with that she also leads the CSR department of the organization.
The first edition of the Uth Series felicitation ceremony was held on January 29, 2026, at the Four Seasons Hotel, Worli, Mumbai. The evening brought together achievers from across industries, celebrating their role in India’s growth story and recognising those setting new benchmarks for the next generation of entrepreneurs.
Speaking on the recognition, Dr. Anar Modi said, “It is a privilege to be recognised among entrepreneurs who are reshaping the landscape of leadership and innovation in India. This honour reaffirms my belief that when growth is guided by purpose and responsibility, it leads to impact that truly endures.”
The Uth Series continues to spotlight trailblazers whose journeys reflect ambition balanced with accountability, and innovation driven by purpose.
About Senores Pharmaceuticals Limited:
Senores Pharmaceuticals Limited (together with its subsidiaries “Senores”) is a global, research driven pharmaceutical company engaged in developing and manufacturing a wide range of pharmaceutical products predominantly for the US, Canada, and other regulated and emerging markets across various therapeutic areas and dosage forms.
The companies’ current portfolio includes 46 ANDAs and 133 strengths along with a pipeline of 22 ANDAs and 52 strengths In the CMO/CDMO vertical 8 ANDAs and 24 products permitted for distribution in the USA along with a pipeline of 16 ANDAs and 57 strengths. Senores is also engaged in the development and manufacturing of complex generics certified by global food and drugs authorities and delivers generic drugs for emerging markets, catering to more than 40 countries. The company currently has approval from regulatory bodies of more than 10 countries for its manufacturing facility in Chhatral for emerging markets with over 394 product registrations and 824 product applications. Senores also manufactures critical care injectables and Active Pharmaceutical Ingredients (“API”).
Senores has 2 manufacturing facilities for formulations – one in Atlanta, US which is USFDA approved and DEA, TAA & BAA compliant for controlled substances and government supplies & other is in Chhatral, Ahmedabad, India approved by WHO-GMP to cater to emerging markets. The company also has 2 manufacturing facilities for API in India, both located around Ahmedabad, with one in Chhatral and the other in Naroda. Senores has strong R&D capabilities to drive differentiated product portfolio across 3 R&D sites (1 in the USA and 2 in India).